Abstract:e14666 Background: The immunotherapy of bone and soft tissue sarcomas remains a challenge. Our pre-clinical trial confirmed that the combination of Toll-like receptor 7 (TLR7) agonist imiquimod (R837) and OX-40 agonist had prominent synergistic effects. Immunoradiotherapy, especially Stereotactic Body Radiotherapy (SBRT) could further activate specific immune response. We hypothesized that intratumoral injection of “RO” (R837+αOX40) combined with SBRT will realize tumor control and reduce adverse reactions. Meanwhile, the synergetic application of PD-1 mAb systematically will improve the effectiveness of immunotherapy. Methods: This is a single-arm, single-center, open-label, exploratory trial that explore intratumoral injection of an emulsion of “RO” in combination with SBRT as “in situ vaccination” for advanced solid tumor (Ethics number: 2021-133-02). The inclusion criteria included: 1) advanced solid tumors which progress after standard therapies, 2) presence of one or more injectable lesions. SBRT to injected lesions was at a dose of 5-8Gy per fraction at a total dose of 20-32Gy. Imiquimod (0.75mg/ml) and αOX40 (2.5mg/ml) were prepared as emulsion and intratumoral injected into the target lesion for 4 times. Patients were also systematically administrated with PD-1 mAb (serplulimab). The primary endpoint was objective response rate (ORR) of target lesions. The secondary endpoint mainly included disease control rate (DCR) of target lesions, progression free survival (PFS), overall survival (OS), and clinical benefit rate (CBR), etc. Results: From May 2021 to October 2022, 30 patients were eligible for this trial (60% were sarcomas). 46.7% and 33.3% had received radiotherapy or PD-1/PD-L1 mAb respectively before. The ORR, DCR and CBR of target lesions were 29.2%, 91.7% and 41.7%, while these of systemic efficacy were 21.7%, 82.6% and 17.4%, respectively. In sarcomas, the ORR, DCR and CBR of target lesions were 25.0%, 93.8% and 50.0%, while these of systemic efficacy were 20.0%, 93.3% and 26.7%, respectively. Systemic median PFS were 3.67 months. The median event-free survival (EFS) of target lesions and median OS were not reached. Among the evaluable target lesions, 6-month EFS was 85.7% in sarcomas (6/7) and 76.9% in all patients (10/13). The most common TRAEs were leukopenia (50%), hypoproteinemia (30%) and anemia (20%), demonstrating that treatment is tolerable. Grade≥3 treatment-related adverse events (TRAE) occurred in 3 patients, including myocarditis (6.7%) and thyroiditis (3.3%). Conclusions: In situ vaccination with “RO” emulsion, along with SBRT was tolerable and induced anti-tumor immunity, which would also trigger systemic response when synergized with PD-1 mAb. This in situ vaccination has been proved to be a promising option for advanced solid tumors especially for sarcomas. Clinical trial information: ChiCTR2100053870 .

Successful Treatment of Rosai–Dorfman Disease Using in Situ Photoimmunotherapy

Granulomatous Rosacea-Like Skin Rash: Extranodal Rosai-Dorfman Disease

Successful treatment of large cutaneous facial Rosai-Dorfman disease using combination of subtotal resection and ALA-PDT: A case report

Treatment of cutaneous Rosai-Dorfman disease with ALA-PDT combined with low-dose oral corticosteroids: A case report

Multifocal Cutaneous Rosai-Dorfman Disease Treated With Localized Radiotherapy

Generalized Pure Cutaneous Rosai-Dorfman Disease: a Link Between Inflammation and Cancer Not Associated with Mitochondrial DNA and SLC29A3 Gene Mutation?

Primary central nervous system Rosai-Dorfman disease: report of 3 cases and review of the literature

Topical photodynamic therapy with 5-aminolevulinic acid in Chinese patients with Rosacea.

Nasal Presentations of Rosai-Dorfman Disease: Clinical Manifestation and Treatment Outcomes

Novel Intense Pulsed Light-Photodynamic Therapy Strategy in the Treatment of Facial Actinic Keratoses Concomitant with Rosacea

Inflammation burst after 5-aminolevulinic acid-photodynamic therapy for the treatment of actinic keratosis complicating rosacea: A case report

An Exploratory Trial of a Novel R-ISV-RO Technique in the Treatment of Advanced Solid Tumors

Photodynamic therapy in the treatment of rosacea: A systematic review

Photodynamic therapy for Cutaneous inflammatory pseudotumour: A case report

Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma

Novel Technique for Rosacea Treatment Using Optimal Pulse Technology: in Vivo and Clinical Studies.

Ferroptosis-apoptosis combined anti-melanoma immunotherapy with a NIR-responsive upconverting mSiO2 photodynamic platform

Combined therapy of 5-aminolevulinic acid photodynamic therapy and intense pulsed light for rosacea

Characteristics of Rosai-Dorfman Disease Primarily Involved in the Central Nervous System: 3 Case Reports and Review of Literature

Pulsed dye laser followed by intradermal botulinum toxin type‐A in the treatment of rosacea‐associated erythema and flushing

Photodynamic Therapy of Bowen's Disease Using 5-Aminolevulinic Acid